For global availability if we have more than one successful candidate we also as the chairman mentioned will be producing that scene at risk which means well be investigating considerable resources in developing doses even before we note any given candidate candidates work i must warn you it is also the possibility of negative consequences for certain that seems can actually enhance that negative effect of the infection the big unknown is efficacy will it be present for absence and how durable will it be and finally i want to mention the n. R. A. Has launched a Public Private partnership called accelerating covert 19 their reputed interventions and vaccines the purpose of that is to prioritize and accelerate clinical evaluation of therapeutic candidates with near term potential hopefully our Research Efforts together with the other public. Efforts to get us quickly to an end to this terrible deal that we are all going through thank you very much happy to answer questions later. Thank y